SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bauer C.) srt2:(1995-1999)"

Sökning: WFRF:(Bauer C.) > (1995-1999)

  • Resultat 1-10 av 13
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • de, Laverny P, et al. (författare)
  • EROS variable stars: discovery of a slow nova in the SMC
  • 1998
  • Ingår i: ASTRONOMY AND ASTROPHYSICS. - : SPRINGER VERLAG. ; 335:3
  • Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
    • We report the discovery of a slow nova found in the core of the Small Magellanic Cloud by the EROS microlensing survey. Nova SMC 1994 is a classical nova with a DQ Her type lightcurve characterized by a deep minimum. Low amplitude variations occurring on
  •  
3.
  •  
4.
  •  
5.
  • Juniper, E F, et al. (författare)
  • Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
  • 1999
  • Ingår i: European Respiratory Journal. - 1399-3003. ; 14:5, s. 1038-1043
  • Tidskriftsartikel (refereegranskat)abstract
    • The Formoterol and Corticosteroids Establishing Therapy (FACET) study has provided the first opportunity to examine the long-term effects of inhaled steroids and long-acting beta2-agonists on asthma-specific quality of life. The objectives of the present study were to: evaluate the effects of long-term (1 yr) formoterol and increasing doses of budesonide on asthma quality of life; 2) to determine whether initial improvements in quality of life are sustained when improvements in clinical indices persist; and 3) to evaluate the long-term relationship between changes in clinical indices and changes in quality of life. Of the 852 asthmatic adults enrolled, 470 from five countries participated in this quality of life evaluation. After a 4-week run-in on 1,600 microg budesonide, patients were randomized to either 200 microg (Bud200) or 800 microg budesonide (Bud800) in combination with either 24 microg formoterol (F) or placebo daily for 1 yr. The Asthma Quality of Life Questionnaire (AQLQ) was completed and conventional clinical indices measured at enrolment and randomization and on seven occasions during the following 12 months. During the run-in, there was an improvement in AQLQ score (changes (delta) in overall score approximately 0.50; p<0.0001). After randomization, there was a further improvement in the Bud800+F group (delta=0.21; p=0.028). One month post-randomization, improvements in all groups stabilized and were sustained throughout the 12 months in a pattern very similar to that observed for the conventional clinical indices. The correlation of individual patient changes in clinical indices and changes in AQLQ score during the 12-month randomized period were weak to moderate (maximum r=0.51). Improvements in quality of life, which were greatest in the 800 microg budesonide plus 24 microg formoterol group, were sustained throughout the 12 months in a similar manner to the clinical indices. Long-term changes in conventional clinical indices cannot be used to predict the effect of treatment on individual patient experience.
  •  
6.
  •  
7.
  • Magnusson, P, et al. (författare)
  • Photometric observations and modeling of asteroid 1620 Geographos
  • 1996
  • Ingår i: ICARUS. - : ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS. - 0019-1035. ; 123:1, s. 227-244
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Photometric observations of 1620 Geographos in 1993 and 1993 are presented and, in combination with previously published data, are used to derive models of Geographos, We estimate that the sidereal period of rotation is 0.21763860 +/- 0.00000003 days (5(h
  •  
8.
  • Sajantila, A, et al. (författare)
  • Paternal and maternal DNA lineages reveal a bottleneck in the founding of the Finnish population
  • 1996
  • Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 93:21, s. 12035-12039
  • Tidskriftsartikel (refereegranskat)abstract
    • An analysis of Y-chromosomal haplotypes in several European populations reveals an almost monomorphic pattern in the Finns, whereas Y-chromosomal diversity is significantly higher in other populations. Furthermore, analyses of nucleotide positions in the mitochondrial control region that evolve slowly show a decrease in genetic diversity in Finns. Thus, relatively few men and women have contributed the genetic lineages that today survive in the Finnish population. This is likely to have caused the so-called ''Finnish disease heritage''-i.e., the occurrence of several genetic diseases in the Finnish population that are rare elsewhere. A preliminary analysis of the mitochondrial mutations that have accumulated subsequent to the bottleneck suggests that it occurred about 4000 years ago, presumably when populations using agriculture and animal husbandry arrived in Finland.
  •  
9.
  • Skytting, Björn T., et al. (författare)
  • Clinical course in synovial sarcoma : A Scandinavian sarcoma group study of 104 patients
  • 1999
  • Ingår i: Acta Orthopaedica Scandinavica. - : Medical Journals Sweden AB. - 0001-6470. ; 70:6, s. 536-542
  • Tidskriftsartikel (refereegranskat)abstract
    • We analyzed treatment and outcome in 104 Scandinavian patients with synovial sarcoma in the extremities or trunk wall, diagnosed between 1986 and 1994. Only surgically treated patients without metastases at diagnosis were included. Median follow-up of survivors was 6 (3-11) years. 34 patients developed metastases. The overall 5- and 7-year survival rates were 0.76 (95% Cl 0.66-0.83) and 0.69 (0.58-0.78), respectively. Large tumor size and amputation were significantly associated with impaired metastasis-free survival. Patients with local recurrence had a higher risk of metastases following the local event. Local excision with inadequate margin was associated with a higher risk of local recurrence.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 13

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy